High-dose everolimus and very low-dose ciclosporin versus mycophenolate sodium and standard-dose ciclosporin for the prevention of renal transplant rejection

Trial Profile

High-dose everolimus and very low-dose ciclosporin versus mycophenolate sodium and standard-dose ciclosporin for the prevention of renal transplant rejection

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2011

At a glance

  • Drugs Everolimus (Primary) ; Mycophenolate sodium (Primary) ; Ciclosporin
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Sep 2011 Status changed from recruiting to completed.
    • 20 Sep 2011 Status changed from completed to recruiting.
    • 07 Sep 2011 Results presented at the 15th Congress of the European Society for Organ Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top